advanced search
2023_June_SMI_London_leaderboard
Dr Julie Suman
Vice-President, Scientific Affairs
Aptar Pharma

Is this your profile?

About

Julie Suman, PhD, is the Vice-President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr Suman is also the co-founder of Next Breath. She holds a BSc in Pharmacy from Duquesne University (Pittsburgh, PA, US)) and a PhD in Pharmaceutical Sciences from the University of Maryland (Baltimore, MD, US). She is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University (VA, US).

Contributions

NASAL
THE POTENTIAL AND THE CHALLENGES OF NASAL VACCINATION
Julie Suman and Nektaria Karavas discuss the challenges and opportunities of intranasal vaccination – showcasing current understanding for both liquid and powder products. Experimental studies highlight critical issues, the performance of commercially available devices and developments in formulation practice.

More contributions

EXPERT VIEW
USING QUALITY BY DESIGN TO OPTIMISE THE COMBINATION PRODUCT JOURNEY
Justin Lacombe and Julie D Suman explain how applying quality by design principles to combination products improves development efficiency, aligns with design controls, and maximises product safety and efficacy.
NASAL
DELIVERING ON THE PROMISES OF INTRANASAL VACCINATION
Julie Suman and Nektaria Karavas review intranasal delivery as a method of vaccine administration and consider the challenges and benefits of intranasal delivery.
NASAL
HOW EVOLVING PATIENT NEEDS HAVE FUELLED THE DEVELOPMENT OF NASAL DRUG DELIVERY
Julie Suman considers how the needs of the patient have driven advances in nasal drug delivery and looks at the latest developments and benefits of this method of drug delivery.
OCULAR
REDUCE RISKS, MITIGATE FAILURE & DRIVE TIMELINES IN A COMPETITIVE MARKET
Badre Hammond, Shailuja Somaraju and Julie Suman highlight key considerations and present strategies to reduce risk and ultimately accelerate the process for gaining approval of an ophthalmic product, with a focus on the US.
Top